Matthew Powell, MD
Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73. Abstract
Eskander RN et al. Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 Study. SGO 2023;Abstract 264.
Giaquinto AN et al. The changing landscape of gynecologic cancer mortality in the United States. Obstet Gynecol 2022;139(3):440-2. Abstract
Makker V et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437-48. Abstract
Mirza MR et al. Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). SGO 2023;Abstract 265.
Pignata S et al. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2023;24(3):286-96. Abstract
Robert Coleman, MD, FACS, FACOG
Makker V et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437-48. Abstract
Makker V et al. Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775. ESMO 2022;Abstract 525MO.
Makker V et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019:20(5):711-8. Abstract
Oaknin A et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. ASCO 2022;Abstract 5509.
Tinker AV et al. Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study. ESMO 2022;Abstract 548P.
Shannon Westin, MD, MPH
How JA et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 2021;162(1):24-31. Abstract
Makker V et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. Oncologist 2021;26(9):e1599-608. Abstract
Brian Slomovitz, MD
Lin MY et al. Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection. Gynecol Oncol 2022;169:91-7. Abstract
Makker V et al. ENGOT-EN20/GOG-3083/XPORT-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial cancer. SGO 2023;Abstract LBA9.
Makker V et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification. ASCO 2022;Abstract 5511.
Slomovitz SM et al. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol 2022;164(3):481-91. Abstract
Vergote IB et al. Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. ESMO Virtual Plenary 2022;Abstract VP2-2022.